HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
Want to see GB:HEMO full AI Analyst Report?
Top Page
HemoGenyx Pharmaceuticals Plc
(LSE:HEMO)
Select Model
Select Model
Rating:42Neutral
Price Target:
662.00 p
▲(16.55% Upside)
Action:Reiterated
Date:05/10/26
Overall score is driven primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn with a leveraged and shrinking equity base). Technicals also weigh on the score as price sits below key moving averages with negative MACD, despite oversold RSI/Stochastic. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Debt reduction
A multi-year reduction in total debt meaningfully lowers financing pressure for a loss-making biotech. Reduced debt cuts future interest/service needs and modestly extends runway, improving the company's ability to fund R&D or negotiate partnerships without immediate refinancing risk.
Negative Factors
Pre-revenue profile
Absence of any revenue forces reliance on external capital and milestone/licensing events to sustain operations. For a development-stage biotech this raises long-term dilution risk, restricts reinvestment capacity, and creates uncertainty around the timing and certainty of commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt reduction
A multi-year reduction in total debt meaningfully lowers financing pressure for a loss-making biotech. Reduced debt cuts future interest/service needs and modestly extends runway, improving the company's ability to fund R&D or negotiate partnerships without immediate refinancing risk.
Read all positive factors
HemoGenyx Pharmaceuticals Plc (HEMO) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£45.83M
Dividend YieldN/A
Average Volume (3M)113.41K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue GrowthN/A
EPS Growth-28.29%
CountryUK
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.21
Shares Outstanding6,799,961
10 Day Avg. Volume30,447
30 Day Avg. Volume113,406
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model
Company Description
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoie...
How the Company Makes Money
Publicly available, specific details describing HemoGenyx Pharmaceuticals Plc’s current revenue model, recurring revenue streams, and monetization mechanisms (e.g., product sales, licensing/royalties, milestone payments, contract services, or mate...
HemoGenyx Pharmaceuticals Plc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
26
Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -588.75K | -639.28K | -645.68K | -2.60M | -283.65K |
| EBITDA | -4.07M | -4.71M | -5.73M | -3.42M | -2.39M |
| Net Income | -9.76M | -5.62M | -6.69M | -3.98M | -5.10M |
Balance Sheet | |||||
| Total Assets | 4.18M | 4.21M | 6.11M | 7.09M | 8.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.59M | 159.26K | 1.25M | 2.53M | 6.84M |
| Total Debt | 2.00M | 2.62M | 2.95M | 3.42M | 10.15K |
| Total Liabilities | 3.03M | 3.36M | 3.32M | 3.85M | 352.84K |
| Stockholders Equity | 1.20M | 897.51K | 2.82M | 3.28M | 8.19M |
Cash Flow | |||||
| Free Cash Flow | -3.45M | -4.13M | -6.22M | -3.34M | -3.45M |
| Operating Cash Flow | -3.45M | -4.12M | -6.11M | -2.91M | -2.63M |
| Investing Cash Flow | -6.80K | -24.90K | -31.94K | -420.25K | -938.95K |
| Financing Cash Flow | 4.89M | 3.08M | 4.45M | -110.14K | 8.78M |
HemoGenyx Pharmaceuticals Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | £33.84M | -4.23 | -55.47% | ― | ― | 19.83% | |
53 Neutral | £51.63M | -1.83 | -14.65% | 2.94% | -25.43% | -155.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £26.83M | -3.00 | -6634.51% | ― | ― | ― | |
46 Neutral | £24.92M | 45.77 | -197.54% | ― | 3.31% | 21.91% | |
42 Neutral | £45.83M | -1.82 | -3931.14% | ― | ― | -28.29% | |
40 Underperform | £19.87M | -6.19 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:HEMO
HemoGenyx Pharmaceuticals Plc
677.50
501.00
283.85%
GB:IMM
ImmuPharma
4.52
1.65
57.77%
GB:HVO
Open Orphan Plc
7.95
-9.25
-53.78%
GB:POLB
Poolbeg Pharma Ltd.
4.80
2.30
92.00%
GB:AREC
Arecor Therapeutics PLC
66.00
24.00
57.14%
GB:APTA
Aptamer Group Plc
0.58
0.20
55.41%
HemoGenyx Pharmaceuticals Plc Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Hemogenyx advances lead CAR-T trial and secures funding to complete Phase 1
Positive
Apr 30, 2026
Hemogenyx Pharmaceuticals reported its final audited results for 2025, highlighting significant clinical and operational progress as it advances its lead CAR-T therapy, HG-CT-1, for relapsed or refractory acute myeloid leukaemia. The company has t...
Business Operations and StrategyPrivate Placements and Financing
Hemogenyx Raises £3m to Accelerate HG-CT-1 Trials and Early Commercialisation
Positive
Apr 28, 2026
Hemogenyx Pharmaceuticals has raised £3 million from a small group of institutional investors via a direct subscription of 374,532 new shares to accelerate clinical development of its CAR-T therapy HG-CT-1. The capital will primarily fund Pha...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Hemogenyx Files Annual FDA IND Report as AML CAR‑T Trial Shows Early Promise
Positive
Apr 14, 2026
Hemogenyx Pharmaceuticals has filed its annual Investigational New Drug report with the U.S. Food and Drug Administration for HG‑CT‑1, its proprietary CAR‑T cell therapy for relapsed or refractory acute myeloid leukemia, summaris...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Hemogenyx Advances HG-CT-1 CAR-T Program With Manufacturing Transfer and Trial Expansion
Positive
Mar 31, 2026
Hemogenyx Pharmaceuticals has completed the technology transfer of manufacturing for its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia to contract developer and manufacturer Made Scientific. A comparability data pack...
Business Operations and StrategyRegulatory Filings and Compliance
Hemogenyx Pharmaceuticals Updates Share Capital and Voting Rights Structure
Neutral
Feb 27, 2026
Hemogenyx Pharmaceuticals plc, a clinical-stage biopharmaceutical group listed on the LSE and focused on therapies for blood and autoimmune diseases, operates from London with U.S. subsidiaries in New York City supporting its pipeline of product c...
Private Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Raises £118,632 Through Warrant Exercise and Expands Share Capital
Positive
Feb 23, 2026
Hemogenyx Pharmaceuticals has received notices to exercise warrants over 50,841 new ordinary shares at prices between 180p and 350p, raising £118,632 in fresh capital. The new shares will be admitted to the FCA’s Official List and to tr...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML
Positive
Feb 10, 2026
Hemogenyx Pharmaceuticals has raised £2.5 million from a consortium of private investors via a direct subscription for 333,333 new shares at £7.50 each, alongside three-year warrants exercisable at £9, increasing its issued share ca...
Business Operations and StrategyPrivate Placements and Financing
Hemogenyx Raises £2.5m to Advance AML CAR-T Trials and Reduce Costs
Positive
Feb 10, 2026
Hemogenyx Pharmaceuticals has raised £2.5 million through a direct subscription of 313,333 new shares at £7.50 each from a consortium of private investors, accompanied by three-year warrants exercisable at £9. The funds will primari...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.